Pub Date : 2026-01-14DOI: 10.1016/s2468-1253(26)00003-8
Jairath V, Danese S, D'Haens GR, et al. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol 2026; 11: 34–45—In this Article, the definition of endoscopic improvement should read “defined as a Mayo endoscopic subscore ≤1”; the definition of the modified Mayo score clinical response should read “defined as a decrease from baseline in the modified Mayo score of ≥2 points and ≥30%, plus a decrease in the rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of 0 or 1”; the definition of Mayo score clinical remission should read “defined as Mayo score ≤2, with no individual subscore >1”; and the definition of modified Mayo score clinical remission should read “defined as a stool frequency subscore of 0 or 1 without worsening, rectal bleeding subscore of 0, and Mayo endoscopic subscore ≤1”. These corrections have been made as of Jan 14, 2026.
{"title":"Correction to Lancet Gastroenterol Hepatol 2026; 11: 34–45","authors":"","doi":"10.1016/s2468-1253(26)00003-8","DOIUrl":"https://doi.org/10.1016/s2468-1253(26)00003-8","url":null,"abstract":"<em>Jairath V, Danese S, D'Haens GR, et al. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.</em> Lancet Gastroenterol Hepatol <em>2026;</em> 11: <em>34–45</em>—In this Article, the definition of endoscopic improvement should read “defined as a Mayo endoscopic subscore ≤1”; the definition of the modified Mayo score clinical response should read “defined as a decrease from baseline in the modified Mayo score of ≥2 points and ≥30%, plus a decrease in the rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of 0 or 1”; the definition of Mayo score clinical remission should read “defined as Mayo score ≤2, with no individual subscore >1”; and the definition of modified Mayo score clinical remission should read “defined as a stool frequency subscore of 0 or 1 without worsening, rectal bleeding subscore of 0, and Mayo endoscopic subscore ≤1”. These corrections have been made as of Jan 14, 2026.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"36 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/s2468-1253(25)00287-0
Thanh N Nguyen, Whitney E Jackson, Nitzan C Roth, Felice Cinque, Monika Sarkar, Niharika Samala, Rita S Lee, Alexandra T Strauss, Jessica Wisocky, Keyur Patel, Giada Sebastiani, Carl G Streed, Jordan E Lake, Tzu-Hao Lee
{"title":"Chronic liver disease and hepatology care in transgender and gender diverse populations","authors":"Thanh N Nguyen, Whitney E Jackson, Nitzan C Roth, Felice Cinque, Monika Sarkar, Niharika Samala, Rita S Lee, Alexandra T Strauss, Jessica Wisocky, Keyur Patel, Giada Sebastiani, Carl G Streed, Jordan E Lake, Tzu-Hao Lee","doi":"10.1016/s2468-1253(25)00287-0","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00287-0","url":null,"abstract":"","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"82 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145962458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1016/s2468-1253(25)00347-4
Nathaniel A Cohen,Dominik Bettenworth,Neta Sror,Raneem Khedraki,Qijun Yang,Maria T Abreu,Raja Atreya,Badr Al-Bawardy,Susan J Connor,Geert D'Haens,Iris Dotan,Axel Dignass,Sara El Ouali,Brian Feagan,Roger Feakins,Richard Gearry,Ilyssa O Gordon,Charlotte R H Hedin,Cristian Hernandez-Rocha,Taku Kobayashi,Haim Leibovitzh,Cathy Lu,Nitsan Maharshak,Maliha Naseer,Jacob Ollech,David T Rubin,Shaji Sebastian,Britta Siegmund,Mark S Silverberg,Flavio Steinwurz,Joana Torres,Gill Watermeyer,Tina Aswani Omprakash,Lior Frenkel,Paige Gurizzian,Alexa Silfen,Roie Tzadok,Katherine Falloon,Florian Rieder,
Patients with Crohn's disease can have isolated or co-existent upper gastrointestinal involvement, but this is an understudied clinical manifestation. There are neither standardised definitions nor diagnostic or management recommendations to help to guide clinical practice. Therefore, we conducted a RAND/University of California Los Angeles appropriateness study on the definition, diagnosis, management, and appropriate outcomes of upper gastrointestinal Crohn's disease (UGICD). An international expert panel of 30 gastroenterologists and pathologists and two patient representatives were recruited. Following a previously published systematic review, 1061 candidate items were grouped into questions and evaluated for appropriateness. Two modified Delphi rounds of voting with an interposed moderated group discussion were performed. The expert panel defined UGICD as disease occurring in the oesophagus, stomach, and/or duodenum (proximal to the ligament of Treitz) that can occur at any time during the disease course. Upper endoscopy is appropriate only in patients with newly diagnosed or existing Crohn's disease with suspicion for upper gastrointestinal involvement (eg, upper gastrointestinal symptoms or the presence of anaemia). Management of UGICD should be determined on a case-by-case basis and factors, such as disease location and symptomatic, endoscopic, and imaging severity, should guide medical, endoscopic, and surgical intervention. Both clinical and endoscopic response and remission are appropriate treatment targets for routine clinical practice; there is uncertainty about the value of histological outcomes in UGICD.
{"title":"Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study.","authors":"Nathaniel A Cohen,Dominik Bettenworth,Neta Sror,Raneem Khedraki,Qijun Yang,Maria T Abreu,Raja Atreya,Badr Al-Bawardy,Susan J Connor,Geert D'Haens,Iris Dotan,Axel Dignass,Sara El Ouali,Brian Feagan,Roger Feakins,Richard Gearry,Ilyssa O Gordon,Charlotte R H Hedin,Cristian Hernandez-Rocha,Taku Kobayashi,Haim Leibovitzh,Cathy Lu,Nitsan Maharshak,Maliha Naseer,Jacob Ollech,David T Rubin,Shaji Sebastian,Britta Siegmund,Mark S Silverberg,Flavio Steinwurz,Joana Torres,Gill Watermeyer,Tina Aswani Omprakash,Lior Frenkel,Paige Gurizzian,Alexa Silfen,Roie Tzadok,Katherine Falloon,Florian Rieder, ","doi":"10.1016/s2468-1253(25)00347-4","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00347-4","url":null,"abstract":"Patients with Crohn's disease can have isolated or co-existent upper gastrointestinal involvement, but this is an understudied clinical manifestation. There are neither standardised definitions nor diagnostic or management recommendations to help to guide clinical practice. Therefore, we conducted a RAND/University of California Los Angeles appropriateness study on the definition, diagnosis, management, and appropriate outcomes of upper gastrointestinal Crohn's disease (UGICD). An international expert panel of 30 gastroenterologists and pathologists and two patient representatives were recruited. Following a previously published systematic review, 1061 candidate items were grouped into questions and evaluated for appropriateness. Two modified Delphi rounds of voting with an interposed moderated group discussion were performed. The expert panel defined UGICD as disease occurring in the oesophagus, stomach, and/or duodenum (proximal to the ligament of Treitz) that can occur at any time during the disease course. Upper endoscopy is appropriate only in patients with newly diagnosed or existing Crohn's disease with suspicion for upper gastrointestinal involvement (eg, upper gastrointestinal symptoms or the presence of anaemia). Management of UGICD should be determined on a case-by-case basis and factors, such as disease location and symptomatic, endoscopic, and imaging severity, should guide medical, endoscopic, and surgical intervention. Both clinical and endoscopic response and remission are appropriate treatment targets for routine clinical practice; there is uncertainty about the value of histological outcomes in UGICD.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"255 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145949779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：